Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in three upcoming virtual investor conferences. Management will present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:00 a.m. ET, followed by the Morgan Stanley Virtual Global Healthcare Conference on September 16, 2020, at 11:00 a.m. ET, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 4:40 p.m. ET. Live webcasts will be available on the Investor Relations section of their website, with archived replays for 90 days.

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:

• Virtual H.C. Wainwright 22nd Annual Global Investment Conference
  Tuesday, September 15, 2020 at 10:00 a.m. ET

• Morgan Stanley Virtual Global Healthcare Conference
  Wednesday, September 16, 2020 at 11:00 a.m. ET

• Cantor Fitzgerald Virtual Global Healthcare Conference
  Thursday, September 17, 2020 at 4:40 p.m. ET

Live audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 90 days after each conference.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates filing an IND in the third quarter with initiation of a clinical trial in the fourth quarter of 2020 with FTX-6058 for the treatment of sickle cell disease.

Please visit www.fulcrumtx.com.

Contact:
Christi Waarich
Director, Investor Relations and
Corporate Communications
cwaarich@fulcrumtx.com
617-651-8664

Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

FAQ

When is Fulcrum Therapeutics participating in the virtual investor conferences?

Fulcrum Therapeutics will participate in the virtual investor conferences on September 15, 16, and 17, 2020.

What time will Fulcrum present at the H.C. Wainwright conference?

Fulcrum will present at the H.C. Wainwright conference on September 15, 2020, at 10:00 a.m. ET.

How can I listen to Fulcrum Therapeutics' conference presentations?

You can listen to Fulcrum's conference presentations via live audio webcasts available on their Investor Relations website.

What products is Fulcrum Therapeutics developing?

Fulcrum is developing losmapimod for facioscapulohumeral muscular dystrophy and COVID-19, alongside FTX-6058 for sickle cell disease.

How long will the archived replays of the presentations be available?

Archived replays of the presentations will be available for 90 days after each conference.